mRNA Therapeutics Market (By Application: Infectious Diseases, Oncology; By Type: Prophylactic Vaccines, Therapeutic Drugs; By End-use) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on MRNA Therapeutics Market 

5.1. COVID-19 Landscape: MRNA Therapeutics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global MRNA Therapeutics Market, By Application

8.1. MRNA Therapeutics Market, by Application, 2024-2033

8.1.1 Rare Genetic Diseases

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Oncology

8.1.2.1. Market Revenue and Forecast (2021-2033)

8.1.3. Respiratory Diseases

8.1.3.1. Market Revenue and Forecast (2021-2033)

8.1.4. Infectious Diseases

8.1.4.1. Market Revenue and Forecast (2021-2033)

8.1.5. Others

8.1.5.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global MRNA Therapeutics Market, By Type

9.1. MRNA Therapeutics Market, by Type, 2024-2033

9.1.1. Prophylactic Vaccines

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Therapeutic Vaccines

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Therapeutic Drugs

9.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global MRNA Therapeutics Market, By End-use 

10.1. MRNA Therapeutics Market, by End-use, 2024-2033

10.1.1. Hospitals & Clinics

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Research Organizations

10.1.2.1. Market Revenue and Forecast (2021-2033)

10.1.3. Others

10.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 11. Global MRNA Therapeutics Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Application (2021-2033)

11.1.2. Market Revenue and Forecast, by Type (2021-2033)

11.1.3. Market Revenue and Forecast, by End-use (2021-2033)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Application (2021-2033)

11.1.4.2. Market Revenue and Forecast, by Type (2021-2033)

11.1.4.3. Market Revenue and Forecast, by End-use (2021-2033)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Application (2021-2033)

11.1.5.2. Market Revenue and Forecast, by Type (2021-2033)

11.1.5.3. Market Revenue and Forecast, by End-use (2021-2033)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Application (2021-2033)

11.2.2. Market Revenue and Forecast, by Type (2021-2033)

11.2.3. Market Revenue and Forecast, by End-use (2021-2033)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Application (2021-2033)

11.2.4.2. Market Revenue and Forecast, by Type (2021-2033)

11.2.4.3. Market Revenue and Forecast, by End-use (2021-2033)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Application (2021-2033)

11.2.5.2. Market Revenue and Forecast, by Type (2021-2033)

11.2.5.3. Market Revenue and Forecast, by End-use (2021-2033)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Application (2021-2033)

11.2.6.2. Market Revenue and Forecast, by Type (2021-2033)

11.2.6.3. Market Revenue and Forecast, by End-use (2021-2033)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Application (2021-2033)

11.2.7.2. Market Revenue and Forecast, by Type (2021-2033)

11.2.7.3. Market Revenue and Forecast, by End-use (2021-2033)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Application (2021-2033)

11.3.2. Market Revenue and Forecast, by Type (2021-2033)

11.3.3. Market Revenue and Forecast, by End-use (2021-2033)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Application (2021-2033)

11.3.4.2. Market Revenue and Forecast, by Type (2021-2033)

11.3.4.3. Market Revenue and Forecast, by End-use (2021-2033)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Application (2021-2033)

11.3.5.2. Market Revenue and Forecast, by Type (2021-2033)

11.3.5.3. Market Revenue and Forecast, by End-use (2021-2033)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Application (2021-2033)

11.3.6.2. Market Revenue and Forecast, by Type (2021-2033)

11.3.6.3. Market Revenue and Forecast, by End-use (2021-2033)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Application (2021-2033)

11.3.7.2. Market Revenue and Forecast, by Type (2021-2033)

11.3.7.3. Market Revenue and Forecast, by End-use (2021-2033)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Application (2021-2033)

11.4.2. Market Revenue and Forecast, by Type (2021-2033)

11.4.3. Market Revenue and Forecast, by End-use (2021-2033)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Application (2021-2033)

11.4.4.2. Market Revenue and Forecast, by Type (2021-2033)

11.4.4.3. Market Revenue and Forecast, by End-use (2021-2033)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Application (2021-2033)

11.4.5.2. Market Revenue and Forecast, by Type (2021-2033)

11.4.5.3. Market Revenue and Forecast, by End-use (2021-2033)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Application (2021-2033)

11.4.6.2. Market Revenue and Forecast, by Type (2021-2033)

11.4.6.3. Market Revenue and Forecast, by End-use (2021-2033)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Application (2021-2033)

11.4.7.2. Market Revenue and Forecast, by Type (2021-2033)

11.4.7.3. Market Revenue and Forecast, by End-use (2021-2033)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Application (2021-2033)

11.5.2. Market Revenue and Forecast, by Type (2021-2033)

11.5.3. Market Revenue and Forecast, by End-use (2021-2033)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Application (2021-2033)

11.5.4.2. Market Revenue and Forecast, by Type (2021-2033)

11.5.4.3. Market Revenue and Forecast, by End-use (2021-2033)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Application (2021-2033)

11.5.5.2. Market Revenue and Forecast, by Type (2021-2033)

11.5.5.3. Market Revenue and Forecast, by End-use (2021-2033)

Chapter 12. Company Profiles

12.1. Moderna, Inc.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. BioNTech SE

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. CureVac N.V.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Arcturus Therapeutics

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Translate Bio, Inc.

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. GSK plc.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Argos Therapeutics Inc.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Sangamo Therapeutics, Inc.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Pfizer Inc.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. AstraZeneca plc.

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Frequently Asked Questions

The global mRNA therapeutics market size was reached at USD 33.3 billion in 2023 and it is projected to hit around USD 39.49 billion by 2033.

The global mRNA therapeutics market is growing at a compound annual growth rate (CAGR) of 1.72% from 2024 to 2033.

The North America region has accounted for the largest mRNA therapeutics market share in 2023.

Report Details

  • Report Code:39429
  • Category:Healthcare
  • No. of Pages:150+
  • Format:PDF/PPT/Excel
  • Published:February 2024
  • Historical Year:2021-2022
  • Base Year:2023
  • Estimated Year:2024-2033

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers